866927-10-8
866927-10-8 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | DMF:30.0(最大浓度 mg/mL);97.04(最大浓度 mM) DMSO:29.0(最大浓度 mg/mL);93.81(最大浓度 mM) DMSO:PBS ( pH 7.2) (1:3):0.25(最大浓度 mg/mL);0.81(最大浓度 mM) 乙醇:1.0(最大浓度 mg/mL);3.23(最大浓度 mM) |
| 形态 | 固体 |
| 颜色 | 粉红至红色 |
866927-10-8 用途与合成方法
IC87201 (500-1800 μM) does not inhibit any of the probe-PDZ interactions involving PDZ1, PDZ2, PDZ3 of PSD-95 or nNOS-PDZ, or bind the canonical PDZ ligand binding sites. IC87201 binds to the β-finger of nNOS-PDZ and allosterically inhibits the nNOS-PDZ/PSD-95-PDZ interactions. IC87201 shows high degree of fluorescence-based artefactual signal when using TAMRA-nNOS as probe. IC87201 (20 μM) suppresses NMDA-stimulated cGMP formation relative to vehicle, in cultured hippocampal neurons. IC87201 (10 and 100 nM) attenuats NMDA/glycine-induced decreases in neurite outgrowth. IC87201 dose-dependently reduces NMDA-induced cGMP production in primary hippocampal neurons (DIV 14-21) with an IC 50 of 2.7 μM. IC87201 increases the number of branches at 10-30 μM when compared to control-treated neurons.
IC87201 (1, 4 and 10 mg/kg, i.p.) does not produce impairment in either spatial working memory or source memory. IC87201 (1 mg/kg) is effective in treating NMDA-induced thermal hyperalgesia in mice, with a corresponding peak plasma level of 55 ng/mL (or 0.2 μM).
866927-10-8 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-100457 | 5 mg | 500 | ||
| 2024-11-08 | HY-100457 | 866927-10-8 | 866927-10-8 | 10mM * 1mLin DMSO | 550 |
